AGEN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Agenus announced an updated NEST Phase 2 publication reporting deep pathological responses and no observed recurrences with neoadjuvant BOT plus BAL in resectable colon cancerAug 26, 2026
- GSK's prefilled syringe presentation of Shingrix receives approval in CanadaJul 24, 2026
- Agenus to present three BOT+BAL studies in colorectal cancer and advanced sarcomas at ESMO 2026Jul 19, 2026
- Agenus enrolled the first patient in a Phase 3 trial of BOT+BAL immunotherapy in colorectal cancerApr 1, 2026
- France grants reimbursed compassionate access (AAC) for Agenus' BOT/BAL in refractory MSS metastatic colorectal cancerSep 9, 2025